These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 21088861

  • 1. In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
    Lascols C, Legrand P, Mérens A, Leclercq R, Armand-Lefevre L, Drugeon HB, Kitzis MD, Muller-Serieys C, Reverdy ME, Roussel-Delvallez M, Moubareck C, Lemire A, Miara A, Gjoklaj M, Soussy CJ.
    Eur J Clin Microbiol Infect Dis; 2011 Apr; 30(4):475-82. PubMed ID: 21088861
    [Abstract] [Full Text] [Related]

  • 2. In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
    Lascols C, Legrand P, Mérens A, Leclercq R, Muller-Serieys C, Drugeon HB, Kitzis MD, Reverdy ME, Roussel-Delvallez M, Moubareck C, Brémont S, Miara A, Gjoklaj M, Soussy CJ.
    Int J Antimicrob Agents; 2011 Mar; 37(3):235-9. PubMed ID: 21295447
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
    Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF.
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4388-99. PubMed ID: 18779357
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS, Hsueh PR, Lee WS, Yu KW, Liao CH, Chang FY, Ko WC, Wu JJ, Chen YH, Chen YS, Liu JW, Lu MC, Liu CY, Lam C, Chen RJ.
    Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea.
    Lee H, Ko KS, Song JH, Peck KR.
    Microb Drug Resist; 2011 Mar; 17(1):37-45. PubMed ID: 20950191
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
    Soussy CJ, Nguyen J, Goldstein F, Dabernat H, Andremont A, Leclercq R, Drugeon H, Cavallo P, Chardon H, Etienne J, Rio Y, Courvalin P.
    Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
    [Abstract] [Full Text] [Related]

  • 12. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.
    Kiratisin P, Chongthaleong A, Tan TY, Lagamayo E, Roberts S, Garcia J, Davies T.
    Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743
    [Abstract] [Full Text] [Related]

  • 13. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V, Söyletir G, Yalçın AN, Oğünç D, Dokuzoğuz B, Esener H, Ulusoy S, Tünger A, Aygen B, Sümerkan B, Arman D, Dizbay M, Akova M, Hasçelik G, Eraksoy H, Başaran S, Köksal I, Bayramoğlu G, Akalın H, Sınırtaş M.
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [Abstract] [Full Text] [Related]

  • 14. Validation of EUCAST zone diameter breakpoints against reference broth microdilution.
    Bengtsson S, Bjelkenbrant C, Kahlmeter G.
    Clin Microbiol Infect; 2014 Jun; 20(6):O353-60. PubMed ID: 24118469
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
    Morfin-Otero R, Noriega ER, Dowzicky MJ.
    Ann Clin Microbiol Antimicrob; 2015 Dec 15; 14():53. PubMed ID: 26667651
    [Abstract] [Full Text] [Related]

  • 16. [Activities of antimicrobial agents against 8,474 clinical isolates obtained from 37 medical institutions during 2000 in Japan].
    Yamaguchi K, Ohno A, Kashitani F, Iwata M, Kanda M, Tsujio Y, Sugiyama T, Toyoshima S, Kato J, Watanabe N, Kaku M, Kanemitsu K, Kunishima H, Kawaguchi H, Okada J, Shimoyama N, Igari J, Oguri T, Kaimori M, Watanabe K, Kobayashi Y, Uchida H, Katayama Y, Sugimoto K, Tashiro H, Kanno H, Yasujima M, Itoh K, Suwabe A, Obata R, Okada M, Kobayashi S, Tsuzimura M, Itoh A, Sumitomo M, Taminato T, Negayama K, Baba H, Makino H, Murase M, Miyamoto H, Minakuchi K, Ishigo S, Takii M, Horii T, Ono J, Takata T, Yamanaka K, Hamazaki N, Tsutsui T, Okabe H, Tatewaki K, Moro K, Hiramatsu K, Saikawa T, Ichiyama S, Nagasawa Z, Aoki Y, Matsushima T, Niki Y, Hirakata Y, Kohno S, Kuwabara M, Nakagawa K, Kageoka T, Hongo T, Yamane N.
    Jpn J Antibiot; 2003 Oct 15; 56(5):341-64. PubMed ID: 14692376
    [Abstract] [Full Text] [Related]

  • 17. Comparison of broth microdilution, agar dilution, and Etest for susceptibility testing of doripenem against gram-negative and gram-positive pathogens.
    Amsler K, Santoro C, Foleno B, Bush K, Flamm R.
    J Clin Microbiol; 2010 Sep 15; 48(9):3353-7. PubMed ID: 20592149
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z, Chen M, Yu Y, Pan S, Liu Y.
    Antimicrob Resist Infect Control; 2018 Sep 15; 7():152. PubMed ID: 30564308
    [Abstract] [Full Text] [Related]

  • 19. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
    Sader HS, Streit JM, Fritsche TR, Jones RN.
    Clin Microbiol Infect; 2006 Sep 15; 12(9):844-52. PubMed ID: 16882289
    [Abstract] [Full Text] [Related]

  • 20. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV, Briceno DF, Ruiz SJ, Furtado GH, Nicolau DP.
    Braz J Infect Dis; 2011 Sep 15; 15(5):413-9. PubMed ID: 22230846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.